NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Novus Therapeutics, Inc.

19900 MacArthur Boulevard
Suite 550
Irvine, CA 92612
United States
949-238-8090
http://novustherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. Gregory J. FlesherCEO & DirectorN/AN/A1970
Dr. Catherine C. Turkel PharmD, MBA, Ph.D.PresN/AN/A1961
Mr. Jon Kuwahara CPASr. VP of Fin. & Admin.N/AN/A1965
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Corporate Governance

Novus Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.